Orforglipron

What is Orforglipron?

Orforglipron, branded as Foundayo by Eli Lilly, is the first FDA-approved oral non-peptide GLP-1 receptor agonist (approved April 1, 2026). Unlike injectable GLP-1 agonists (semaglutide, tirzepatide) and even oral semaglutide (which requires SNAC absorption enhancer technology and strict fasting), orforglipron is a small molecule that can be taken as a simple daily tablet without food restrictions. It is technically not a peptide — it's a small molecule that mimics GLP-1 signaling — but it targets the same receptor and belongs to the same therapeutic class as semaglutide and tirzepatide. The FDA approved Foundayo for chronic weight management in adults with obesity, or in adults with overweight plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia), as an adjunct to a reduced-calorie diet and increased physical activity. Approval came via the FDA's Commissioner's National Priority Voucher pilot program in just 50 days from filing — the fastest new molecular entity approval since 2002. The approved tablet formulation uses stepped dose titration starting at 0.8 mg once daily and escalating every 30 days to a maximum maintenance dose of 17.2 mg (the Phase 3 trials used 6 mg, 12 mg, and 36 mg capsule doses; the approved tablet doses are different per the PMID 41994902 bioequivalence study). Phase 3 trials support the approval across several journals: ATTAIN-1 (obesity) and ACHIEVE-1 (early T2D) in the New England Journal of Medicine, ATTAIN-2 (obesity with T2D) in The Lancet, and ATTAIN-MAINTAIN (weight maintenance) in Nature Medicine. By September 2026 the ACHIEVE type 2 diabetes program was also largely published, including ACHIEVE-3 — a 52-week head-to-head trial in which orforglipron lowered HbA1c more than oral semaglutide (Rybelsus). The UK regulator (MHRA) had approved Foundayo for weight loss by August 2026.

What Orforglipron Is Investigated For

Orforglipron (Foundayo) is Eli Lilly's FDA-approved oral small-molecule GLP-1 receptor agonist for chronic weight management, with additional studied indications across type 2 diabetes, weight maintenance after injectable GLP-1 therapy, and broader cardiometabolic risk reduction. The strongest evidence is in obesity, with Phase 3 trials published in the New England Journal of Medicine, The Lancet, and Nature Medicine — ATTAIN-1 produced 11.2% weight loss at the highest dose over 72 weeks in 3,127 patients, ATTAIN-2 added efficacy in patients with T2D, ATTAIN-MAINTAIN demonstrated weight maintenance after switching from injectable GLP-1 therapy, and ACHIEVE-1 showed glycemic benefit in early T2D. The type 2 diabetes program has since filled out: ACHIEVE-3 (Lancet 2026, n=1,698) beat oral semaglutide on HbA1c at 52 weeks, ACHIEVE-2 (Lancet 2026, n=962) beat dapagliflozin at 40 weeks, ACHIEVE-5 (JAMA 2026, n=546) added benefit on top of insulin glargine without clinically significant hypoglycemia, and ACHIEVE-J (Lancet Diabetes Endocrinol 2026) supplied 52-week safety data in Japanese patients. The honest framing on the evidence is that orforglipron is clinically meaningful but produces somewhat less peak weight loss than injectable semaglutide (~14%) and substantially less than tirzepatide (~20%) — its differentiator is convenience (daily pill, no fasting required, no injection), not superior efficacy. The FDA approved Foundayo on April 1, 2026 via the Commissioner's National Priority Voucher pilot program, the fastest NME approval since 2002 (50 days from filing). The approved label covers chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related comorbidity (hypertension, T2D, dyslipidemia). Cardiovascular outcomes data is still pending (no dedicated CVOT equivalent to SELECT or SURPASS-CVOT). Long-term safety beyond the 72-week Phase 3 window remains an open question. T2D as a standalone indication has not yet been approved in the US.

History & Discovery

Orforglipron (Lilly internal designation LY3502970) originated from Chugai Pharmaceutical's small-molecule GLP-1 receptor agonist program and was licensed by Eli Lilly in 2018. Its development is a notable chapter in GLP-1 history because it represents a deliberate attempt to achieve GLP-1 receptor agonism through a non-peptide small-molecule structure — sidestepping the oral bioavailability problem that historically made GLP-1 agonists injection-only, and doing so without the absorption-enhancer workarounds (SNAC technology) required for oral semaglutide. Phase 1 dose-escalation and safety studies were published in 2023. Phase 2 data in obesity and type 2 diabetes, also published in 2023 in the New England Journal of Medicine, established clinically meaningful weight loss and HbA1c reduction and supported advancement to large Phase 3 programs. Between 2024 and early 2026, Lilly reported results across the ACHIEVE series (type 2 diabetes) and ATTAIN series (obesity). ACHIEVE-1 reported positive topline efficacy in early type 2 diabetes in 2025. ATTAIN-1 demonstrated up to 11.2% mean weight loss at 36 mg over 72 weeks in a 3,127-participant obesity cohort. ATTAIN-2 evaluated obesity in people with type 2 diabetes. ATTAIN-MAINTAIN tested whether patients switching from injectable GLP-1s could maintain weight loss on oral orforglipron (published in Nature Medicine, May 2026, PMID 42120723). The regulatory inflection arrived on April 1, 2026, when the FDA approved Foundayo for chronic weight management in adults with obesity, or in adults with overweight plus at least one weight-related comorbidity (hypertension, T2D, dyslipidemia), as an adjunct to a reduced-calorie diet and increased physical activity. The approval came through the FDA's Commissioner's National Priority Voucher pilot program — 50 days from filing to approval, the fastest new molecular entity (NME) approval since 2002. The approved label carries the GLP-1-class boxed warning for thyroid C-cell tumors (contraindication in personal or family history of MTC or MEN 2). Foundayo's commercial formulation is a tablet (distinct from the Phase 3 capsule), with stepped dose titration starting at 0.8 mg once daily and escalating every 30 days to a maximum maintenance dose of 17.2 mg — supported by the PMID 41994902 bioequivalence study comparing tablet and capsule formulations. Foundayo entered the US market in April 2026. It is the first FDA-approved oral non-peptide GLP-1 receptor agonist — a meaningful milestone for oral incretin therapy, particularly versus the SNAC-dependent oral semaglutide formulation (Rybelsus). Through mid-2026 the diabetes program reached print. ACHIEVE-3 (Rosenstock et al., Lancet, March 2026) became the first randomized head-to-head between two oral GLP-1 drugs, with orforglipron lowering HbA1c more than oral semaglutide at both dose comparisons over 52 weeks. ACHIEVE-2 (Lancet, July 2026) beat dapagliflozin, ACHIEVE-5 (JAMA, August 2026) showed added benefit on top of insulin glargine, and ACHIEVE-J (Lancet Diabetes Endocrinol, October 2026) reported 52-week safety in Japanese patients. Internationally, the UK's MHRA had approved Foundayo for weight loss by August 2026, and applications are under review in the EU, Japan, and Canada. Further Phase 3 programs are under way in obstructive sleep apnea, hypertension, stress urinary incontinence, osteoarthritis pain, and peripheral arterial disease.

How It Works

Foundayo (orforglipron) is a pill that mimics the GLP-1 hormone — the same target as Ozempic and Mounjaro. It tells your brain you're full, slows stomach emptying, and helps your body manage blood sugar. The breakthrough is that it's a small molecule rather than a peptide, so it survives digestion and can be taken as a simple daily pill.

Orforglipron is a non-peptide, small-molecule agonist of the GLP-1 receptor. Unlike peptide-based GLP-1 agonists that require injection or specialized oral delivery technology (SNAC for oral semaglutide), orforglipron's small-molecule structure confers oral bioavailability without absorption enhancers. It activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin secretion), hypothalamic appetite centers (reducing food intake), and gastric smooth muscle (slowing gastric emptying). Phase 3 data from ATTAIN-1 (3,127 participants, 72 weeks) demonstrated dose-dependent weight loss: -7.5% (6 mg), -8.4% (12 mg), and -11.2% (36 mg) vs -2.1% placebo. At 36 mg, 54.6% achieved at least 10% weight loss and 18.4% achieved at least 20%. Secondary improvements included waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol. The ATTAIN-MAINTAIN trial demonstrated successful weight maintenance when patients switched from injectable GLP-1s to oral orforglipron. Because orforglipron is a small molecule rather than a peptide, it is also handled by drug-metabolizing machinery that peptide GLP-1s bypass: it is a substrate of CYP3A4, the OATP1B1/1B3 hepatic uptake transporters, and P-glycoprotein, which is why strong CYP3A4/P-gp inhibitors (clarithromycin, cyclosporine) raise its exposure and inducers (carbamazepine) lower it (Morse et al., Clin Pharmacol Ther 2026). A pooled analysis of 11,220 participants across seven Phase 3 trials found no cases meeting drug-induced liver injury (Hy's Law) criteria (Wharton et al., Diabetes Obes Metab 2026).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Orforglipron:

• 01Cardiovascular outcomes — a dedicated cardiovascular outcomes trial comparable to semaglutide's SELECT or tirzepatide's SURPASS-CVOT has not read out for orforglipron (its CVOT, ACHIEVE-4, had not been published as of September 2026). CVOT data is typically required for GLP-1 labels extending beyond glycemic control, and orforglipron's positioning on cardiovascular risk reduction will depend on forthcoming trial readouts.
• 02Long-term safety beyond the 72-week Phase 3 window — chronic use data beyond trial duration does not yet exist, and GLP-1 agonists are chronic therapies for obesity and T2D.
• 03Head-to-head versus injectable GLP-1 and GLP-1/GIP agonists — direct comparative efficacy versus injectable semaglutide 2.4 mg and tirzepatide in obesity is not established in randomized comparisons; existing comparisons are cross-trial. The only randomized head-to-head so far is ACHIEVE-3, against oral semaglutide in type 2 diabetes.
• 04New indications — Phase 3 programs are listed in obstructive sleep apnea, hypertension, stress urinary incontinence in women, osteoarthritis pain, and peripheral arterial disease (Drugs 'First Approval' review, 2026); none has reported yet.
• 05Pediatric and adolescent efficacy and safety — not yet studied.
• 06Effect on longer-term metabolic health markers (lean mass preservation, bone density, non-alcoholic fatty liver disease endpoints) — these are active questions across the GLP-1 class and not yet fully resolved for orforglipron.
• 07Real-world adherence and discontinuation dynamics — trial-setting adherence typically exceeds real-world adherence, and how orforglipron's oral-without-food-restrictions profile translates to real-world persistence is not yet known.

Forms & Administration

Orforglipron is taken as a once-daily oral tablet (Foundayo). The approved label uses stepped dose titration starting at 0.8 mg once daily, with escalation every 30 days to a maintenance dose up to 17.2 mg max. Note: this differs from the Phase 3 trial dosing (6 mg, 12 mg, and 36 mg capsules) because the approved commercial formulation is a tablet with different pharmacokinetics — the PMID 41994902 bioequivalence study supported the tablet-formulation dose conversion. The tablet does not require fasting or special administration conditions.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

These doses reflect the FDA-approved Foundayo label as of April 2026. Foundayo is a prescription medication and should be used under the supervision of a qualified healthcare provider. The trial-era capsule doses (6/12/36 mg) circulating in older orforglipron coverage do not match the approved tablet label.

Timeline of Effects

Common Questions

Who Orforglipron Is NOT For

Drug & Supplement Interactions

Orforglipron's small-molecule structure means its interaction profile is different from peptide GLP-1 agonists in important ways, but several class-level concerns still apply. Gastric emptying is delayed by GLP-1 receptor activation, which can alter the absorption of concomitant oral medications — particularly those with narrow therapeutic windows or rapid-onset requirements. Patients taking oral medications requiring rapid absorption (such as certain hypnotics, analgesics, or emergency medications) should be aware that onset timing may shift. Concurrent use with other glucose-lowering agents, particularly sulfonylureas and insulin, increases hypoglycemia risk and typically requires dose adjustment of those agents. As a small molecule, orforglipron has enzyme- and transporter-level interactions that peptide GLP-1 agonists do not. Six dedicated Phase 1 studies (Morse et al., Clin Pharmacol Ther 2026) characterized it as a substrate of CYP3A4, the hepatic uptake transporters OATP1B1/1B3, and P-glycoprotein. Clarithromycin (a strong CYP3A4/P-gp inhibitor) and cyclosporine (which also blocks OATP transporters) increased orforglipron exposure, while carbamazepine (a CYP3A4 inducer) decreased it. In the other direction, orforglipron had minimal effect on the exposure of midazolam, digoxin, and statins, so it does not appear to be a meaningful perpetrator of interactions. Patients on strong CYP3A4 inhibitors or inducers, or on transplant immunosuppression, should have that flagged when Foundayo is prescribed; the FDA label is the authoritative source for specific dose guidance. Concurrent use with other GLP-1 receptor agonists or dual agonists (tirzepatide, semaglutide, liraglutide) is not clinically indicated and would compound both efficacy and adverse-event profile.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions